Literature DB >> 15345765

Multimodal treatment for ADHD among youths in three Medicaid subgroups: disabled, foster care, and low income.

Susan dosReis1, Pamela L Owens, Karen B Puccia, Philip J Leaf.   

Abstract

OBJECTIVE: This study compared the use of treatments for attention-deficit hyperactivity disorder (ADHD) among three distinct subpopulations of Medicaid-insured youths who have very different mental health needs and patterns of service use: those with federally documented disability, those in foster care, and those in families with low income.
METHODS: This one-year, cross-sectional study of community mental health services used administrative data. Individuals who were younger than 20 years, who were continuously enrolled in one Mid-Atlantic state Medicaid program, and who had two or more medical encounters associated with an ADHD diagnosis in 1998 were identified (N=1,296). Measures of the use of mental health services were the number of different classes of psychopharmacologic medications, the psychopharmacologic regimen, and the combined use of pharmacotherapy and psychotherapy treatments (multimodal treatment).
RESULTS: Use of multiple psychopharmacologic agents was greater in the disabled and foster care groups compared with the low-income group. Significantly fewer mental health provider visits, but greater use of stimulant treatment only, were observed in the low-income group compared with the other groups. Youths in the disabled group were significantly more likely than youths in the low-income group, but not more likely than youths in the foster care group, to receive multimodal treatments. Children in foster care were significantly more likely than those in the other groups to use a substance abuse service.
CONCLUSIONS: Among a cohort of Medicaid-enrolled youths with ADHD, co-existing psychiatric disorders and complex psychopharmacologic treatments were more common in the disabled and foster care groups than in the low-income group. Youths with disabilities were significantly more likely than youths in the low-income group to receive multimodal treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15345765     DOI: 10.1176/appi.ps.55.9.1041

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  7 in total

1.  Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.

Authors:  Catherine A Fullerton; Arnold M Epstein; Richard G Frank; Sharon-Lise T Normand; Christina X Fu; Thomas G McGuire
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

2.  Child sociodemographic characteristics and common psychiatric diagnoses in medicaid encounter data: are they valid?

Authors:  Penelope K Knapp; Michael S Hurlburt; Eric C Kostello; Heather Ladd; Lingqi Tang; Bonnie T Zima
Journal:  J Behav Health Serv Res       Date:  2006-10       Impact factor: 1.505

Review 3.  Psychosocial treatments for children with attention deficit/hyperactivity disorder.

Authors:  Brian P Daly; Torrey Creed; Melissa Xanthopoulos; Ronald T Brown
Journal:  Neuropsychol Rev       Date:  2007-03       Impact factor: 7.444

4.  Treatment for ADHD: is more complex treatment cost-effective for more complex cases?

Authors:  E Michael Foster; Peter S Jensen; Michael Schlander; William E Pelham; Lily Hechtman; L Eugene Arnold; James M Swanson; Timothy Wigal
Journal:  Health Serv Res       Date:  2007-02       Impact factor: 3.402

5.  Deficits in diagnosis, treatment and continuity of care in African-American children and adolescents with ADHD.

Authors:  Heather Hervey-Jumper; Karl Douyon; Kathleen N Franco
Journal:  J Natl Med Assoc       Date:  2006-02       Impact factor: 1.798

Review 6.  Pediatric Integrative Medicine Approaches to Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Anna Esparham; Randall G Evans; Leigh E Wagner; Jeanne A Drisko
Journal:  Children (Basel)       Date:  2014-08-27

7.  Stimulant and atypical antipsychotic medications for children placed in foster homes.

Authors:  L Oriana Linares; Nuria Martinez-Martin; F Xavier Castellanos
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.